HIGH POINT, N.C., Feb. 10, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced positive results from Part 2 of the Phase 2 Simplici-T1 trial assessing TTP399 as an oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results